Overview
Biote focuses on hormone optimization using clinically validated medical approaches to identify and treat imbalances in hormone production. It uses lab testing and medical assessment to pinpoint hormone deficiencies or excesses, then prescribes personalized treatment plans—often including bio-identical hormone therapy and related regimens—under medical supervision to restore balanced hormone levels. Biote differentiates itself through its emphasis on translating extensive scientific insight (80+ years of research) into validated protocols and continuing medical oversight, rather than generic supplements. The company’s goal is to help patients achieve balanced hormone levels and improve health outcomes by delivering scientifically grounded, physician-guided hormone optimization.
Work here?Claim your company
Simplify's take
What believers are saying
- Q3 2026 revenue reached $43.3 million, and management kept full-year guidance unchanged.
- Dietary supplements grew 7.3% in Q3 2026, cushioning procedure declines.
- Biote named Komal Bajaj chief medical officer on June 1, 2026.
What critics are saying
- Procedure revenue fell 15.1% in Q3 2026 after the January recall.
- Biote booked $5.1 million in legal settlement charges during 2026.
- FDA scrutiny of compounded pellets threatens Biote's practitioner network and core economics.
What makes Biote unique
- Biote controls hormone-optimization training, branded procedures, and supplements across a practitioner network.
- Its 2026 revenue still leans on proprietary pellets and recurring supplement sales.
- Biote's November 2026 results show 67.7% gross margin despite recall damage.
Help us improve and share your feedback! Did you find this helpful?